Revista Brasileira de Hematologia e Hemoterapia Revista Brasileira de Hematologia e Hemoterapia
Rev Bras Hematol Hemoter 2017;39:183-5 DOI: 10.1016/j.bjhh.2017.02.005
Letter to the Editor
Stathmin 1 expression in plasma cell neoplasms
João Agostinho Machado-Netoa, , Fernando Vieira Pericolea, Fernando Ferreira Costaa, Fabiola Trainaa,b, Sara Teresinha Olalla Saada,,
a Universidade Estadual de Campinas/Hemocentro (UNICAMP), Campinas, SP, Brazil
b Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil
Recebido 21 Outubro 2016, Aceitaram 08 Fevereiro 2017
Dear Editor,

Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of malignant plasma cells which accumulate in the bone marrow, resulting in recurrent hypercalcemia, anemia, osteolytic lesions, renal failure, and increased risk of infection.1 Stathmin 1, also named oncoprotein 18 (OP18) or leukemia-associated phosphoprotein p18 (LAP18), is a microtubule destabilizer that plays an important role in cell progression, clonogenicity, differentiation and survival.2 Stathmin 1 overexpression has been reported in hematological malignancies, including acute myeloid leukemia, acute lymphoid leukemia, lymphoma, high-risk myelodysplastic syndromes and primary myelofibrosis.3–7 Functional studies indicate that high stathmin 1 expression is able to sustain rapid cell division and proliferation of leukemia cells, which are suppressed by stathmin 1 inhibition.5,8,9 Using the microarray approach, stathmin 1 has been identified as one of 15 relevant genes that determine the outcome in MM patients.10

The aim of the present study was to investigate Stathmin 1 expression in respect to clinical and laboratorial characteristics, and outcomes of MM patients. Bone marrow samples collected from healthy donors (n=21, median age 33 years; range: 18–69), MM patients (n=30; median age 64 years; range: 45–86) and plasma cell leukemia patients (PCL; n=4; median age 72 years; range: 68–84) were analyzed. All patients included in the study were untreated at the time of sample collection. Patients’ characteristics are listed in Table 1. All healthy controls and patients provided informed written consent and the study was approved by the Research Ethics Committee of the Universidade Estadual de Campinas. MM patients received cyclophosphamide, thalidomide and dexamethasone (CTD; n=15), bortezomib, thalidomide and dexamethasone (VTD; n=1), CTD/VTD (n=4), or melphalan, prednisolone and thalidomide (MPT; n=9) protocol treatments or watchful waiting (n=1). Total RNA was obtained from total bone marrow cells after removal of erythrocytes by hemolysis using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The genomic DNA was eliminated using DNAse I treatment (Invitrogen). The cDNA was obtained from 1μg of RNA using the RevertAid™ First Strand cDNA Synthesis Kit (MBI Fermentas, St. Leon-Rot, Germany). An aliquot of 120ng of cDNA was used for gene expression analysis by quantitative polymerase chain reaction (qPCR) in the ABI 7500 Sequence Detection System (Applied Biosystem, Foster City, CA, USA) using specific primers for Stathmin 1 (FW: AGCCCTCGGTCAAAAGAATC; RV: TTCAAGACCTCAGCTTCATGGG) and hypoxanthine phosphoribosyltransferase 1 (HPRT1) (FW: GAACGTCTTGCTCGAGATGTGA; RV: TCCAGCAGGTCAGCAAAGAAT) and the Maxima Sybr green qPCR system (MBI Fermentas). HPRT1 was used as the gene reference. Reaction conditions for RNA extraction, cDNA synthesis and qPCR were performed according to the manufactures’ instructions. A negative ‘no template control’ was included for each primer pair. The dissociation protocol was performed at the end of each run to check for nonspecific amplification. Three replicas were run on the same plate for each sample. The relative gene expression was calculated using the equation, 2−ΔΔCT.11 Additional details of qPCR experiments will be provided upon request. A statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). For comparisons, the Kruskal–Wallis test with Dunn's post test was used for measured variables with three levels and the chi-squared test was used for categorical variables. Cox regression was used to estimate overall survival (OS) and progression free survival (PFS). OS was defined as the time (in months) between the date of sampling and the date of death (for deceased patients) or last follow-up (for censored patients). PFS was defined as the time (in months) between the sampling and the date of the first event (symptomatic progression based on the International Myeloma Working Group criteria12 or death) or last follow-up (for censored patients). A p-value<0.05 was considered statistically significant.

Table 1.

The association between clinical and laboratorial characteristics of multiple myeloma patients and Stathmin 1 expression.

Factors  n=30  Stathmin 1 expressionap-Value 
    Low  High   
Age (years)  64 (45–86)       
<60  10  0.12 
≥60  20  12   
Gender         
Male  17  0.71 
Female  13   
Isotype         
IgG  20  12  0.12 
IgA   
Light chain   
ISS         
0.62 
II  10   
III  16   
N/A   
Albumin (g/L)  36.8 (29.9–46.6)       
<35  10  0.52 
≥35  19  10   
N/A   
Hemoglobin (g/L)  88 (67.8–176)       
<100  18  11  0.07 
≥100  11   
N/A   
β2-Microglobulin (pg/mL)  5650 (1900–3040)       
<3500  0.54 
≥3500  25  13  12   
N/A   
BM plasma cells rate (%)  29 (1–68)       
<10  0.92 
≥10–30  12   
≥30  12   
N/A   
Therapeutic outcome
VGPR/PR  8/11  5/5  3/6  0.91 
SD/PD  6/1  3/0  3/1   
Early death   

ISS: International Staging System; BM: bone marrow; VGPR: very good partial response; PR: partial response; SD: stable disease; PD: progressive disease.

a

Multiple myeloma patients were divided into groups based on Stathmin 1 expression; Low Stathmin 1 expression was defined as lower median values and high Stathmin 1 expression was defined as higher median values.

The expressions of Stathmin 1 transcripts were similar between healthy donors (median: 1.00; range: 0.28–1.84), and MM (median: 0.86: range: 0.30–2.89) and PCL (median: 0.79; range: 0.41–4.38) patients (p-value >0.05; Figure 1A). To evaluate the correlation of Stathmin 1 expression with clinical and laboratorial factors further, MM patients were divided into two groups based on median Stathmin 1 levels: high Stathmin 1 expression (median: 1.43; range: 0.89–2.89) and low Stathmin 1 expression (median: 0.62; range: 0.30–0.83). In our cohort of MM patients, no associations were observed between Stathmin 1 expression and clinical factors, laboratorial factors or therapy response ratios (Table 1). Stathmin 1 expression did not affect PFS (low Stathmin 1 expression versus high Stathmin 1 expression – hazard ratio: 1.08; 95% confidence interval: 0.46–2.53; p-value=0.87) nor OS (low Stathmin 1 expression versus high Stathmin 1 expression – hazard ratio: 0.77; 95% confidence interval: 0.28–2.18; p-value=0.68) (Figure 1B and C).

Figure 1.
(0.19MB).

Stathmin 1 expression in plasma cell neoplasms. (A) Quantitative polymerase chain reaction analysis of Stathmin 1 mRNA expression in bone marrow cells from healthy donors, and from patients with multiple myeloma (MM) or plasma cell leukemia (PCL). The hypoxanthine phosphoribosyltransferase 1 gene was used as the reference gene and a healthy donor was used as a calibrator sample. Horizontal lines indicate medians. Progression free survival (B) and overall survival (C) of MM patients stratified by median Stathmin 1 expression. p-Values were calculated by the Long-rank test.

In summary, our findings suggest that Stathmin 1 expression is not differently expressed in plasma cell neoplasms and has no impact upon MM outcomes when considered as an isolated factor. These results highlight that Stathmin 1 overexpression may be linked to high proliferate hematological malignancies as MM is characterized by slow proliferation of malignant plasma cells in the bone marrow.13,14 Future studies using larger cohorts and functional investigations are necessary before disregarding the involvement of Stathmin 1 in the malignant phenotype of plasma cell neoplasms.

Conflict of interest

The authors declare no conflicts of interest.

References
1
A. Palumbo,K. Anderson
Multiple myeloma
N Engl J Med, 364 (2011), pp. 1046-1060 http://dx.doi.org/10.1056/NEJMra1011442
2
B. Belletti,G. Baldassarre
Stathmin: a protein with many tasks. New biomarker and potential target in cancer
Expert Opin Ther Targets, 15 (2011), pp. 1249-1266 http://dx.doi.org/10.1517/14728222.2011.620951
3
S.M. Hanash,J.R. Strahler,R. Kuick,E.H. Chu,D. Nichols
Identification of a polypeptide associated with the malignant phenotype in acute leukemia
J Biol Chem, 263 (1988), pp. 12813-12815
4
G. Roos,G. Brattsand,G. Landberg,U. Marklund,M. Gullberg
Expression of oncoprotein 18 in human leukemias and lymphomas
Leukemia, 7 (1993), pp. 1538-1546
5
J.A. Machado-Neto,P. de Melo Campos,P. Favaro,M. Lazarini,I. Lorand-Metze,F.F. Costa
Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells
6
K. Nylander,U. Marklund,G. Brattsand,M. Gullberg,G. Roos
Immunohistochemical detection of oncoprotein 18 (Op18) in malignant lymphomas
Histochem J, 27 (1995), pp. 155-160
7
J.A. Machado-Neto,P. de Melo Campos,P. Favaro,M. Lazarini,A. da Silva Santos Duarte,I. Lorand-Metze
Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells
Oncotarget, 6 (2015), pp. 29573-29584 http://dx.doi.org/10.18632/oncotarget.4998
8
S. Jeha,X.N. Luo,M. Beran,H. Kantarjian,G.F. Atweh
Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells
Cancer Res, 56 (1996), pp. 1445-1450
9
C. Iancu,S.J. Mistry,S. Arkin,S. Wallenstein,G.F. Atweh
Effects of stathmin inhibition on the mitotic spindle
J Cell Sci, 114 (2001), pp. 909-916
10
O. Decaux,L. Lode,F. Magrangeas,C. Charbonnel,W. Gouraud,P. Jezequel
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome
J Clin Oncol, 26 (2008), pp. 4798-4805 http://dx.doi.org/10.1200/JCO.2007.13.8545
11
K.J. Livak,T.D. Schmittgen
Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method
Methods, 25 (2001), pp. 402-408 http://dx.doi.org/10.1006/meth.2001.1262
12
R.A. Kyle,S.V. Rajkumar
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
13
D. Puthier,C. Pellat-Deceunynck,S. Barille,N. Robillard,M.J. Rapp,N. Juge-Morineau
Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy
Leukemia, 13 (1999), pp. 289-294
14
V. Scudla,M. Ordeltova,J. Bacovsky,M. Vytrasova,P. Horak,J. Minarik
The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma
Haematologica, 90 (2005), pp. 1713-1714
Copyright © 2017. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
Rev Bras Hematol Hemoter 2017;39:183-5 DOI: 10.1016/j.bjhh.2017.02.005